Table 4.
Factors associated with anti-hypertensive prescription among HIV-infected persons and matched controls in the study cohort.
| HIV infected |
Controls |
|||
|---|---|---|---|---|
| Unadjusted OR (95% CI)a |
Adjusted OR (95% CI)a,b |
Unadjusted OR (95% CI)a |
Adjusted OR (95% CI)a,b |
|
| Age (per 10 years) |
2.15
(1.74–2.65) |
n/a |
1.58
(1.26–1.96) |
n/a |
| Male sex | 1.08 (0.78–1.50) |
n/a | 1.11 (0.80–1.53) |
n/a |
| Race | ||||
| White | 1.00 (Ref) | n/a | 1.00 (Ref) | n/a |
| Non-White |
1.33
(1.01–1.75) |
n/a |
1.46
(1.11–1.94) |
n/a |
| Insurance | ||||
| Public | 1.24 (0.93–1.65) |
0.79 (0.50–1.26) |
0.81 (0.61–1.07) |
0.98 (0.59–1.61) |
| Private | 0.93 (0.70–1.22) |
0.90 (0.56–1.41) |
1.22 (0.92–1.61) |
0.71 (0.43–1.18) |
| None | 0.96 (0.66–1.38) |
1.18 (0.77–1.80) |
1.28 (0.84–1.94) |
1.19 (0.74–1.90) |
| Tobacco use | 1.22 (0.91–1.61) |
1.28 (0.92–1.78) |
1.04 (1.00–1.75) |
1.10 (0.77–1.60) |
| Cocaine use | 1.08 (0.72–1.64) |
1.20 (0.73–1.97) |
1.12 (0.77–1.62) |
0.93 (0.55–1.58) |
| Diabetes |
3.50
(2.04–5.39) |
3.36
(1.83–6.16) |
5.35
(3.49–8.20) |
5.28
(3.18–8.76) |
| Mean SBP (per 10 mmHg) |
1.77
(1.56–2.00) |
1.77
(1.54–6.16) |
2.48
(2.12–2.89) |
2.62
(2.19–3.13) |
| Mean total cholesterol (per 10 mg/dL) |
1.01 (0.98–1.04) |
1.01 (0.96–1.07) |
0.95
(0.92–0.99) |
0.96 (0.90–1.02) |
| Mean LDL cholesterol (per 10 mg/dL) |
1.02 (0.98–1.06) |
1.01 (0.94–1.08) |
0.94
(0.90–0.99) |
1.00 (0.92–1.08) |
| Mean HDL cholesterol (per 10 mg/dL) |
0.98 (0.91–1.06) |
0.97 (0.89–1.06) |
0.89
(0.81–0.98) |
0.96 (0.86–1.07) |
Note: Bold, meets statistical significance at p-value < 0.05.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; n/ a, not applicable; OR, odds ratio; ref, reference.
a
Logistic regression.
b
Adjusting for all relevant clinical risk factors discussed in text.